Showing results (131-140 of 143) with videos related to
Sort By:
Pageof 15
Nature Structural & Molecular Biology|November 16, 2004
Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibitionJeffrey F Ohren, Huifen Chen, Alexander Pavlovsky, et al.Cancer Research|January 20, 2022
Targeting Squalene Epoxidase Interrupts Homologous Recombination via the ER Stress Response and Promotes Radiotherapy EfficacyZhipeng Hong, Tao Liu, Lingfeng Wan, et al.Bioorganic & Medicinal Chemistry Letters|May 15, 2021
Development of BET inhibitors as potential treatments for cancer: A search for structural diversityMatthew D Hill, Haiquan Fang, John Tokarski, et al.Bioorganic & Medicinal Chemistry Letters|September 24, 2021
Development of BET inhibitors as potential treatments for cancer: A new carboline chemotypeMatthew D Hill, Claude Quesnelle, John Tokarski, et al.Journal of Structural Biology|December 19, 2007
Rational protein engineering in action: the first crystal structure of a phenylalanine tRNA synthetase from Staphylococcus haemolyticusArtem G Evdokimov, Marlene Mekel, Kim Hutchings, et al.Bioorganic & Medicinal Chemistry Letters|August 18, 2020
Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studiesZilun Hu, Cailan Wang, Peter W Glunz, et al.Antioxidants & Redox Signaling|January 8, 2014
Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalaginXuan Zou, Chunhong Yan, Yujie Shi, et al.Bioorganic & Medicinal Chemistry Letters|April 13, 2023
Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1Jay A Markwalder, Aaron J Balog, David K Williams, et al.ACS Medicinal Chemistry Letters|February 20, 2020
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology AgentUpender Velaparthi, Chetan Padmakar Darne, Jayakumar Warrier, et al.ACS Medicinal Chemistry Letters|July 21, 2022
Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic PropertiesMatthew D Hill, Haiquan Fang, Derek Norris, et al.Pageof 15